The role of iron and copper in the aetiology of neurodegenerative disorders: Therapeutic implications

George Perry, Lawrence M. Sayre, Craig S. Atwood, Rudolph J. Castellani, Adam D. Cash, Catherine Rottkamp, Mark A. Smith

Research output: Contribution to journalReview article

124 Scopus citations

Abstract

Abnormalities in the metabolism of the transition metals iron and copper have been demonstrated to play a crucial role in the pathogenesis of various neurodegenerative diseases. Metal homeostasis as it pertains to alterations in brain function in neurodegenerative diseases is reviewed in this article in depth. While there is documented evidence for alterations in the homeostasis, redox-activity and localisation of transition metals, it is also important to realise that alterations in specific copper- and iron-containing metalloenzymes appear to play a crucial role in the neurodegenerative process. These changes provide the opportunity to identify pathways where modification of the disease process can occur, potentially offering opportunities for clinical intervention. As understanding of disease aetiology evolves, so do the tools with which diseases are treated. In this article, we examine not only the possible mechanism of disease but also how pharmaceuticals may intervene, from direct and indirect antioxidant therapy to strategies involving gene therapy.

Original languageEnglish (US)
Pages (from-to)339-352
Number of pages14
JournalCNS Drugs
Volume16
Issue number5
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The role of iron and copper in the aetiology of neurodegenerative disorders: Therapeutic implications'. Together they form a unique fingerprint.

  • Cite this

    Perry, G., Sayre, L. M., Atwood, C. S., Castellani, R. J., Cash, A. D., Rottkamp, C., & Smith, M. A. (2002). The role of iron and copper in the aetiology of neurodegenerative disorders: Therapeutic implications. CNS Drugs, 16(5), 339-352. https://doi.org/10.2165/00023210-200216050-00006